Clinical trial

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

NCT07723469

Study summary

ClinicalTrials.gov

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention BCS + SRG-514 Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention BCS Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE3

Conditions

TNBC - Triple-Negative Breast Cancerunresolved

Interventions

BCS + SRG-514DRUG

BCSPROCEDURE

Sponsors & collaborators

SURGE Therapeuticslead sponsor

Mapped research locations

New YorkNew York, United States1 DurhamNorth Carolina, United States1 RochesterMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07723469 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.